Lacosamide Hikma (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, which stabilizes hyperexcitable neuronal membranes and reduces repetitive firing. This action helps to prevent the spread of seizure activity in the brain.

The specific dose and infusion rate of Lacosamide Hikma are determined by the prescribing clinician based on the patient’s clinical condition, age, weight, renal and hepatic function, and response to therapy.

Safety data for lacosamide in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional antiepileptics that target fast inactivation. This can provide additive seizure control when combined with other agents, and it is generally well‑tolerated, though individual response varies.

Lacosamide Hikma should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use to maintain stability.

The product is supplied as an intravenous solution and is administered by slow infusion under the supervision of a qualified healthcare professional, following the dosing schedule prescribed by the treating physician.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and respiratory depression. Patients should be monitored closely for these events, especially during initiation and dose adjustments.

Lacosamide Hikma is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation, and it should be used with caution in individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, or those taking interacting medications.